FDA Launches AI Pilot to Turbocharge Early Drug Trials
Published Date: 5/28/2026
Notice
Summary
The FDA is giving people more time to share their thoughts on a new pilot program that uses AI to make early clinical trials faster and smarter. This program could help researchers make better decisions and speed up how new medicines are tested. If you want to weigh in, you now have until June 29, 2026, to send your comments—no money changes yet, but this could shake up how trials run in the future!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
2026-10621 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
2026-10603 — Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10479 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
The FDA just announced that certain estrogen-androgen combo drugs, like Syntest D.S. and Syntest H.S., aren’t proven effective and can’t be sold unless they have official approval. This affects drug makers and sellers who must stop interstate shipments of these products by June 26, 2026. If you’re involved, it’s time to get compliant or say goodbye to these meds on the market!
2026-10372 — Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
The FDA wants your thoughts on how they collect info about making custom human drugs under special rules (Sections 503A and 503B). This affects pharmacies and drug makers who mix medicines just for patients. You’ve got until July 27, 2026, to share your comments—no cost changes yet, just a chance to help shape the paperwork process!
Previous / Next Documents
Previous: 2026-10601 — Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension: Rule 17a-22
The SEC is asking to keep a rule that makes clearing agencies share important updates on their websites within two days. This helps the SEC keep an eye on changes and make sure everything’s fair and clear. Seven active clearing agencies spend about 15 minutes per update, totaling around 210 hours a year, with no new costs or big changes planned.
Next: 2026-10603 — Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!